These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 10886792

  • 1. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
    Veeken H, Ritmeijer K, Seaman J, Davidson R.
    Trop Med Int Health; 2000 May; 5(5):312-7. PubMed ID: 10886792
    [Abstract] [Full Text] [Related]

  • 2. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
    Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, Davidson RN.
    Trans R Soc Trop Med Hyg; 2001 May; 95(6):668-72. PubMed ID: 11816442
    [Abstract] [Full Text] [Related]

  • 3. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
    Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, Davidson RN.
    Bull World Health Organ; 2001 May; 79(5):388-93. PubMed ID: 11417033
    [Abstract] [Full Text] [Related]

  • 4. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM, Mumina A, Tayler-Smith K, Boulle P, Alcoba G, Elhag MS, Alnour M, Shah S, Chappuis F, van Griensven J, Zachariah R.
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [Abstract] [Full Text] [Related]

  • 5. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
    Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN.
    Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635
    [Abstract] [Full Text] [Related]

  • 6. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
    Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE, Aboud MH, Noazin S, Ghalib HW, El-Hassan AM, Leishmaniasis Research Group/Sudan.
    Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805
    [Abstract] [Full Text] [Related]

  • 7. Sodium stibogluconate cardiotoxicity and safety of generics.
    Rijal S, Chappuis F, Singh R, Boelaert M, Loutan L, Koirala S.
    Trans R Soc Trop Med Hyg; 2003 Jan; 97(5):597-8. PubMed ID: 15307436
    [Abstract] [Full Text] [Related]

  • 8. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.
    Clin Infect Dis; 2006 Aug 01; 43(3):357-64. PubMed ID: 16804852
    [Abstract] [Full Text] [Related]

  • 9. Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate.
    Salih MAM, Fakiola M, Lyons PA, Younis BM, Musa AM, Elhassan AM, Anderson D, Syn G, Ibrahim ME, Blackwell JM, Mohamed HS.
    Parasite Immunol; 2017 Jun 01; 39(6):. PubMed ID: 28370072
    [Abstract] [Full Text] [Related]

  • 10. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
    Dube A, Singh N, Sundar S, Singh N.
    Parasitol Res; 2005 Jun 01; 96(4):216-23. PubMed ID: 15868188
    [Abstract] [Full Text] [Related]

  • 11. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.
    Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, Das ML, Desjeux P, Loutan L, Koirala S.
    Trans R Soc Trop Med Hyg; 2003 Jun 01; 97(3):350-4. PubMed ID: 15228258
    [Abstract] [Full Text] [Related]

  • 12. Combination therapy in Kala-azar.
    Singh NK, Jha TK, Singh IJ, Jha S.
    J Assoc Physicians India; 1995 May 01; 43(5):319-20. PubMed ID: 9081958
    [Abstract] [Full Text] [Related]

  • 13. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
    Gebreyohannes EA, Bhagvathula AS, Abegaz TM, Seid MA.
    Infect Dis Poverty; 2018 Oct 19; 7(1):108. PubMed ID: 30340519
    [Abstract] [Full Text] [Related]

  • 14. Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond.
    Khalil EA, el Hassan AM, Zijlstra EE, Hashim FA, Ibrahim ME, Ghalib HW, Ali MS.
    Ann Trop Med Parasitol; 1998 Mar 19; 92(2):151-8. PubMed ID: 9625910
    [Abstract] [Full Text] [Related]

  • 15. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis.
    Ramesh V, Kumar J, Kumar D, Salotra P.
    Indian J Dermatol Venereol Leprol; 2010 Mar 19; 76(2):138-44. PubMed ID: 20228542
    [Abstract] [Full Text] [Related]

  • 16. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
    Karki P, Koirala S, Parija SC, Hansdak SG, Das ML.
    Southeast Asian J Trop Med Public Health; 1998 Mar 19; 29(1):154-8. PubMed ID: 9740292
    [Abstract] [Full Text] [Related]

  • 17. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.
    Soto J, Valda-Rodriquez L, Toledo J, Vera-Navarro L, Luz M, Monasterios-Torrico H, Vega J, Berman J.
    Am J Trop Med Hyg; 2004 Nov 19; 71(5):577-81. PubMed ID: 15569787
    [Abstract] [Full Text] [Related]

  • 18. Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis.
    Yesilova Y, Surucu HA, Ardic N, Aksoy M, Yesilova A, Oghumu S, Satoskar AR.
    J Dermatolog Treat; 2016 Nov 19; 27(1):83-7. PubMed ID: 26105204
    [Abstract] [Full Text] [Related]

  • 19. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK.
    Natl Med J India; 2005 Nov 19; 18(3):131-3. PubMed ID: 16130613
    [Abstract] [Full Text] [Related]

  • 20. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
    Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J.
    PLoS Negl Trop Dis; 2014 May 19; 8(5):e2875. PubMed ID: 24854196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.